Venkat Nageswar Chalasani resigns as Independent Director of Aurobindo Pharma arm Apitoria Pharma

Published On 2023-11-17 08:00 GMT   |   Update On 2023-11-18 11:29 GMT

Hyderabad: Through a recent BSE filing, Aurobindo Pharma has recently informed that Venkat Nageswar Chalasani has resigned as the Independent Director of Apitoria Pharma Private Limited, a wholly-owned subsidiary of the Company, with effect from November 13, 2023, due to his other preoccupation, i.e. he has been appointed as Chief Executive of the Association of Mutual Funds in India and...

Login or Register to read the full article

HyderabadThrough a recent BSE filing, Aurobindo Pharma has recently informed that Venkat Nageswar Chalasani has resigned as the Independent Director of Apitoria Pharma Private Limited, a wholly-owned subsidiary of the Company, with effect from November 13, 2023, due to his other preoccupation, i.e. he has been appointed as Chief Executive of the Association of Mutual Funds in India and to avoid conflict of interest.

Mr. Venkat Nageswar retired as Deputy Managing Director, International Banking Group of State Bank of India on April 30, 2021. With over 37 years of experience spanning across various distinguished positions in the Bank pan India and abroad, he worked in all the areas of Banking - Credit, Treasury, Retail, International Banking, Finance, Risk Management etc. He has also held CFO position of the Bank for a brief period. He has been part of committees set up by the Reserve Bank of India (RBI) and the Ministry of Finance. He has also been the Chairman of the Fixed Income Money Market and Derivatives Association of India (FIMMDA) and the Foreign Exchange Dealers Association of India (FEDAI).

Read also: Aurobindo Pharma arm Apitoria Pharma appoints new CEO, Independent Director

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 24 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company’s product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, AntiRetroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic.

Read also: Aurobindo Pharma appoints Dr Satakarni Makkapati as Non executive, Non independent Director

Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News